May 10, 2017
After completing Phase II trials, a pill called ABX464 has proven to reduce HIV reservoirs, which can ultimately become part of an HIV cure.
seen from Australia
seen from Netherlands
seen from Malaysia
seen from Brazil
seen from Türkiye
seen from Malaysia
seen from Singapore
seen from China
seen from China
seen from Czechia
seen from Russia
seen from China
seen from United Kingdom
seen from United Kingdom
seen from China
seen from China
seen from Australia
seen from United States
seen from United States
seen from United States
After completing Phase II trials, a pill called ABX464 has proven to reduce HIV reservoirs, which can ultimately become part of an HIV cure.
Abivax lève 750 millions de dollars aux États-Unis pour accélérer le développement de son traitement phare contre les maladies inflammatoires
Une levée de fonds historique pour la biotech française La société Abivax, spécialisée dans le développement de traitements innovants pour les maladies inflammatoires chroniques, a annoncé avoir levé près de 750 millions de dollars aux États-Unis via une importante offre publique d’American Depositary Shares (ADS) sur le Nasdaq. Cette opération constitue l’une des plus grosses levées de fonds…
ABX 464
ABX-464 Molecular FormulaC16H10ClF3N2OAverrage mass338.712 Da SPL-4641258453-75-6[RN]26RU378B9V2-Quinolinamine, 8-chloro-N-[4-(trifluoromethoxy)phenyl]-8-Chloro-N-[4-(trifluoromethoxy)phenyl]-2-quinolinamine EX-A3322, DB14828, SB18690, BS-14770 Abivax is developing ABX464 a lead from HIV-1 splicing inhibitors, which modulates biogenesis of viral RNA, and acts by targeting the Rev protein, for…
View On WordPress
Centros no Sul iniciam testes clínicos de medicamento francês contra Covid-19
Centros no Sul iniciam testes clínicos de medicamento francês contra Covid-19
A região Sul do Brasil está participando do estudo clínico miR-AGE, utilizando um novo medicamento francês, aprovado pela ANVISA, com potencial para tratar a Covid-19. Ao todo, são 4 centros no Sul que estão recrutando pacientes para participarem dos testes: Hospital das Clínicas de Porto Alegre (Porto Alegre), Hospital Tacchini (Bento Gonçalves), Hospital Regional Hans Dieter Schmidt…
View On WordPress
La molécule ABX464 pourrait bien changer la donne dans la recherche de nouveaux traitements efficaces contre le Sida. Les essais cliniques menés par la société héraultaise AVIBAX, en collaboration avec le Centre National de la
ABX464 - has shown potential in reduction of HIV reservoirs as demonstrated by a small scale study measuring total HIV DNA in peripheral blood mononuclear cells (PBMCs).